Drugs / 18F-SF12051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05564429 | Feb → May 2023 | — | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-SF12051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05564429 ↗ |
| Modality | Diagnostic / imaging agent | “[(18)F]SF51, a novel (18)F-labeled PET radioligand for translocator protein 18kDa (TSPO) in brain, works well in monkeys but fails in humans.” PMID 39654356 ↗ Dec 2024 |
| Route | Intravenous | “Healthy participants with HAB TSPO genotype receive 18F-SF12051 intravenously followed by whole body or brain positron emission tomography (PET) scan.” NCT05564429 ↗ |
| Target | TSPO | “[18F]SF51 is a novel radioligand for imaging translocator protein 18 kDa (TSPO) that previously displayed excellent imaging properties in nonhuman primates.” PMID 39654356 ↗ Dec 2024 |